Airway mucosal blood flow in bronchial asthma

S. D. Kumar, M. J. Emery, N. D. Atkins, I. Danta, Adam Wanner

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

As an inflammatory airway disease, asthma is expected to be associated with an increase in airway blood flow. We therefore compared airway mucosal blood flow (Q(aw)) among normal subjects (n = 11) and patients with stable asthma receiving (n = 13) or not receiving (n = 10) long-term inhaled glucocorticosteroid (GS) therapy. Q(aw) was calculated from the uptake of dimethyl ether in the anatomic dead space minus the most proximal 50 ml (DS), and expressed as blood flow per ml DS. Mean (+ SE) Q(aw) was 38.5 ± 5.3 μl · min-1 · ml-1 in normals, 68.2 ± 7.9 μl · min-1 · ml-1 in GS- naive asthmatics (p < 0.01), and 55.4 ± 5.3 μl · min-1 · ml-1 in GS- treated asthmatics (p < 0.05). Ten minutes after administration of 180 μg albuterol by metered dose inhaler, mean Q(aw) increased by 83 ± 26% in normal subjects (p < 0.01), but did not change significantly in GS-naive (+5 ± 8%) or GS-treated (+32 ± 15%) asthmatics. These results demonstrate that Q(aw) is increased in stable asthmatics and resistant to further increase by a standard inhaled dose of a beta-adrenergic agonist.

Original languageEnglish
Pages (from-to)153-156
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume158
Issue number1
StatePublished - Jul 31 1998

Fingerprint

Asthma
Metered Dose Inhalers
Adrenergic beta-Agonists
Albuterol
Therapeutics
dimethyl ether

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Kumar, S. D., Emery, M. J., Atkins, N. D., Danta, I., & Wanner, A. (1998). Airway mucosal blood flow in bronchial asthma. American Journal of Respiratory and Critical Care Medicine, 158(1), 153-156.

Airway mucosal blood flow in bronchial asthma. / Kumar, S. D.; Emery, M. J.; Atkins, N. D.; Danta, I.; Wanner, Adam.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 158, No. 1, 31.07.1998, p. 153-156.

Research output: Contribution to journalArticle

Kumar, SD, Emery, MJ, Atkins, ND, Danta, I & Wanner, A 1998, 'Airway mucosal blood flow in bronchial asthma', American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 1, pp. 153-156.
Kumar, S. D. ; Emery, M. J. ; Atkins, N. D. ; Danta, I. ; Wanner, Adam. / Airway mucosal blood flow in bronchial asthma. In: American Journal of Respiratory and Critical Care Medicine. 1998 ; Vol. 158, No. 1. pp. 153-156.
@article{161289e0225d4e60ae86fdc96e674fce,
title = "Airway mucosal blood flow in bronchial asthma",
abstract = "As an inflammatory airway disease, asthma is expected to be associated with an increase in airway blood flow. We therefore compared airway mucosal blood flow (Q(aw)) among normal subjects (n = 11) and patients with stable asthma receiving (n = 13) or not receiving (n = 10) long-term inhaled glucocorticosteroid (GS) therapy. Q(aw) was calculated from the uptake of dimethyl ether in the anatomic dead space minus the most proximal 50 ml (DS), and expressed as blood flow per ml DS. Mean (+ SE) Q(aw) was 38.5 ± 5.3 μl · min-1 · ml-1 in normals, 68.2 ± 7.9 μl · min-1 · ml-1 in GS- naive asthmatics (p < 0.01), and 55.4 ± 5.3 μl · min-1 · ml-1 in GS- treated asthmatics (p < 0.05). Ten minutes after administration of 180 μg albuterol by metered dose inhaler, mean Q(aw) increased by 83 ± 26{\%} in normal subjects (p < 0.01), but did not change significantly in GS-naive (+5 ± 8{\%}) or GS-treated (+32 ± 15{\%}) asthmatics. These results demonstrate that Q(aw) is increased in stable asthmatics and resistant to further increase by a standard inhaled dose of a beta-adrenergic agonist.",
author = "Kumar, {S. D.} and Emery, {M. J.} and Atkins, {N. D.} and I. Danta and Adam Wanner",
year = "1998",
month = "7",
day = "31",
language = "English",
volume = "158",
pages = "153--156",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Airway mucosal blood flow in bronchial asthma

AU - Kumar, S. D.

AU - Emery, M. J.

AU - Atkins, N. D.

AU - Danta, I.

AU - Wanner, Adam

PY - 1998/7/31

Y1 - 1998/7/31

N2 - As an inflammatory airway disease, asthma is expected to be associated with an increase in airway blood flow. We therefore compared airway mucosal blood flow (Q(aw)) among normal subjects (n = 11) and patients with stable asthma receiving (n = 13) or not receiving (n = 10) long-term inhaled glucocorticosteroid (GS) therapy. Q(aw) was calculated from the uptake of dimethyl ether in the anatomic dead space minus the most proximal 50 ml (DS), and expressed as blood flow per ml DS. Mean (+ SE) Q(aw) was 38.5 ± 5.3 μl · min-1 · ml-1 in normals, 68.2 ± 7.9 μl · min-1 · ml-1 in GS- naive asthmatics (p < 0.01), and 55.4 ± 5.3 μl · min-1 · ml-1 in GS- treated asthmatics (p < 0.05). Ten minutes after administration of 180 μg albuterol by metered dose inhaler, mean Q(aw) increased by 83 ± 26% in normal subjects (p < 0.01), but did not change significantly in GS-naive (+5 ± 8%) or GS-treated (+32 ± 15%) asthmatics. These results demonstrate that Q(aw) is increased in stable asthmatics and resistant to further increase by a standard inhaled dose of a beta-adrenergic agonist.

AB - As an inflammatory airway disease, asthma is expected to be associated with an increase in airway blood flow. We therefore compared airway mucosal blood flow (Q(aw)) among normal subjects (n = 11) and patients with stable asthma receiving (n = 13) or not receiving (n = 10) long-term inhaled glucocorticosteroid (GS) therapy. Q(aw) was calculated from the uptake of dimethyl ether in the anatomic dead space minus the most proximal 50 ml (DS), and expressed as blood flow per ml DS. Mean (+ SE) Q(aw) was 38.5 ± 5.3 μl · min-1 · ml-1 in normals, 68.2 ± 7.9 μl · min-1 · ml-1 in GS- naive asthmatics (p < 0.01), and 55.4 ± 5.3 μl · min-1 · ml-1 in GS- treated asthmatics (p < 0.05). Ten minutes after administration of 180 μg albuterol by metered dose inhaler, mean Q(aw) increased by 83 ± 26% in normal subjects (p < 0.01), but did not change significantly in GS-naive (+5 ± 8%) or GS-treated (+32 ± 15%) asthmatics. These results demonstrate that Q(aw) is increased in stable asthmatics and resistant to further increase by a standard inhaled dose of a beta-adrenergic agonist.

UR - http://www.scopus.com/inward/record.url?scp=0031820246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031820246&partnerID=8YFLogxK

M3 - Article

VL - 158

SP - 153

EP - 156

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -